KEN FRAZIER: I don’t believe it’s had an effect on Merck, because I think the company will continue and has continued to engage the administration, both houses of Congress and policymakers on the key issues that make a difference for innovation and for patient access. ADI IGNATIUS: Do you feel the way many CEOs do that the business model is perpetually changing in two years, five years down the road it may be something completely different, and you’re trying to run a business while also reinventing the future? KEN FRAZIER: I would like people to say that Merck continues to be a company that makes a difference in the world.